Company Filing History:
Years Active: 2011-2012
Title: Jari Mikkola: Innovator in Anti-VAP-1 Therapeutics
Introduction
Jari Mikkola is a notable inventor based in Turku, Finland. He has made significant contributions to the field of therapeutic antibodies, particularly in the treatment of inflammatory conditions. With a focus on VAP-1-mediated adhesion, his work has the potential to impact various medical applications.
Latest Patents
Jari Mikkola holds 2 patents related to his innovative research. His latest patents include methods of treating an inflammatory condition involving VAP-1-mediated adhesion with VAP-1-specific antibodies. These patents disclose novel fully human anti-VAP-1 antibodies and fragments, as well as nucleic acids encoding these antibodies. Additionally, they cover expression vectors and host cells for the recombinant expression of anti-VAP-1 antibodies, along with pharmaceutical compositions and therapeutic uses. Another patent focuses on fully human anti-VAP-1 monoclonal antibodies, detailing similar innovations in the field.
Career Highlights
Jari Mikkola is associated with Biotie Therapies Corporation, where he continues to advance his research and development efforts. His work is pivotal in the exploration of new therapeutic avenues for inflammatory conditions.
Collaborations
Throughout his career, Jari has collaborated with notable colleagues, including David Smith and Petri Vainio. These partnerships have contributed to the success of his research initiatives.
Conclusion
Jari Mikkola's contributions to the field of therapeutic antibodies, particularly in the context of VAP-1, highlight his role as an influential inventor. His patents and ongoing work at Biotie Therapies Corporation underscore the importance of innovation in medical research.